

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 8-K

HEMISPHERX BIOPHARMA INC
Form 8-K
December 20, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
December 20, 2004

HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

Delaware 0-27072 52-0845822
(state or other juris- (Commission (I.R.S. Employer
diction of incorporation) File Number) (Identification No.)

1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (215) 988-0080

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

As agreed with the Company at the outset of becoming a director, having served for a period of 1 year, Dr. Antoni Esteve has resigned as a director. Dr. Esteve will continue to meet with top management of the Company on an ongoing basis with regard to its developmental drug Ampligen, with particular focus on the HIV/HCV clinical trial using Ampligen being conducted in Spain by Laboratorios del Dr. Esteve, S.A. in collaboration with the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX BIOPHARMA, INC.

Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 8-K

December 20, 2004

By: /s/William A. Carter

William A. Carter, M.D.,
President